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SerpinB3 has been recently described as an early marker of liver carcinogenesis, but the potential 
mechanistic role of this serpin in tumor development is still poorly understood. Overexpression 
of Myc often correlates with more aggressive tumour forms, supporting its involvement in 
carcinogenesis. Yes-associated protein (Yap), the main effector of the Hippo pathway, is a central 
regulator of proliferation and it has been found up-regulated in hepatocellular carcinomas. The study 
has been designed to investigate and characterize the interplay and functional modulation of Myc 
by SerpinB3 in liver cancer. Results from this study indicate that Myc was up-regulated by SerpinB3 
through calpain and Hippo-dependent molecular mechanisms in transgenic mice and hepatoma cells 
overexpressing human SerpinB3, and also in human hepatocellular carcinomas. Human recombinant 
SerpinB3 was capable to inhibit the activity of Calpain in vitro, likely reducing its ability to cleave 
Myc in its non oncogenic Myc-nick cytoplasmic form. SerpinB3 indirectly increased the transcription 
of Myc through the induction of Yap pathway. These findings provide for the first time evidence that 
SerpinB3 can improve the production of Myc through direct and indirect mechanisms that include the 
inhibition of generation of its cytoplasmic form and the activation of Yap pathway.
Primary liver cancer, mainly hepatocellular carcinoma (HCC), is one of the leading causes of cancer-related 
death worldwide1 and generally has a poor prognosis since it is often diagnosed at an advanced stage 
when treatment is not effective. Great efforts have been made to decipher the molecular mechanisms 
of HCC and gene expression profiling has been used to identify subgroups of patients according to 
etiological factors, early pre-neoplastic lesions, stage of the disease, rate of recurrence and survival2–5. 
Genetic analysis has revealed that Myc oncogene over-expression is present in up to 70% of viral and 
alcohol-related HCCs. Myc is a potent activator of tumorigenesis and its deregulation has been shown 
to contribute to a variety of cancers6–8. Increased Myc levels often correlate with the more advanced and 
aggressive tumour forms, providing a characteristic signature of cancer progenitor cells and suggesting 
that its overexpression plays some part in Myc-driven pathogenesis and tumor biology9,10.
The Myc oncoprotein is a pleiotropic transcription factor belonging to the basic helix-loop-helix-leucine 
zipper family with a critical role in engaging and coordinating expression of the genes necessary for 
efficient and ordered proliferation of somatic cells. Myc expression is highly regulated being tightly con-
trolled by a number of mechanisms involving many transcriptional regulatory motifs11,12. According to 
its well established predominant role Myc regulates up to 15% of human genes and is involved in cell 
growth, proliferation, metabolism, differentiation, and apoptosis6.
According to data emerging from genome-wide gene expression profiling13 Myc has been recently 
suggested to be at the centre of human liver tumor malignant conversion.
As expected, given their broad role as transcriptional regulator, Myc family proteins are predom-
inantly localized within nuclear compartment during proliferation, although emerging data indicate 
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that Myc biology may be even more complex. Accordingly, a recent finding suggests that the cysteine 
protease Calpain can convert Myc into Myc-nick, a calpain cleavage product which lacks the nuclear 
localization signal and DNA-binding domain, regulating alpha-tubulin acetylation and promoting cell 
differentiation14.
Along these lines, the Yes-associated protein (Yap) is a critical regulator of proliferation, liver size and 
self-renewal of normal and cancer stem cells15. This oncogene is the main effector of the Hippo pathway, 
and it is up-regulated in almost 62% of HCC tissues16. Yap protein is usually detected at low level in 
differentiated hepatocytes, with the signal being diffuse throughout the cell17, but in poorly differentiated 
cancer cells high levels of Yap can be detected within the nuclear compartment. Pertinent to this study, 
recent data suggest that Yap can exert part of its oncogenic activities in liver cancer cells also through 
the modulation of Myc18.
SerpinB3, a member of the ovalbumin-serine proteases inhibitor family (ov-serpins)19, has been 
detected in several malignancies of epithelial origin, including HCC20–23. In the liver, SerpinB3 is almost 
undetectable in normal hepatocytes but it is progressively up-regulated in liver cirrhosis, dysplastic nod-
ules and hepatocellular carcinoma, suggesting that this serpin may be involved in the early events of 
hepatocarcinogenesis24,25.
This serpin determines apoptosis resistance26,27 and induces cell proliferation and deregulation of 
adhesion processes, leading to epithelial-to-mesenchymal transition (EMT) and increased invasiveness28. 
Moreover, transgenic mice over-expressing SerpinB3 showed higher liver regenerative capacity compared 
to wild-type mice, suggesting a role of this protein in promoting cell growth29. Recent studies indicate 
that SerpinB3 is up-regulated by oncogenic Ras, promotes NF-kB-related inflammatory cytokine produc-
tion30 and induces IL-6 autocrine signaling31, favouring tumour progression. These findings are in keep-
ing with the reported high levels of SerpinB3 detected in the sub-class of HCCs with poor prognosis32.
A previous study from our group has shown that SerpinB3 is expressed in the majority of hepatoblas-
tomas, where SerpinB3 levels were positively correlated with the extent of Myc expression and tumour 
diffusion33. Although SerpinB3 has been described as an early marker of liver carcinogenesis, the poten-
tial mechanistic role of SerpinB3 as a mediator of HCC development is still poorly understood. Since 
this serpin is emerging as a relevant hinge for the aggressive phenotype of primary liver cancers and 
Myc overexpression is associated with poor prognosis, the working hypothesis is that SerpinB3 might 
be involved in the deregulation of Myc oncogene and that its relationships with Myc expression may be 
critical for liver carcinogenesis.
Results
Expression and localization of Myc in relation to SerpinB3. In order to investigate whether 
SerpinB3 has a role in Myc regulation, the expression of Myc was explored in different models. In both 
HepG2 and Huh7 cells stably transfected to overexpress SerpinB3, Myc transcript levels were found 
significantly increased, as compared to parental cells (Fig. 1a). At protein level, subcellular analysis per-
formed in transfected HepG2 cells versus parental cells revealed a pronounced nuclear increase, as doc-
umented by Western blot (Fig. 1b) and by immunofluorescence (Fig. 2) analysis, respectively.
Myc expression was then assessed in liver specimens obtained from C57BL6 transgenic mice over-
expressing SerpinB3 and from Serpinb3a(− /− ) mice. SerpinB3 transgenic mice showed a significant 
increase of nuclear Myc protein levels versus respective controls as evaluated in the representative Western 
blot analysis of Fig.  1c. Results obtained in the additional animals analyzed is shown in Supplemental 
Fig. 1. Immunohistochemistry confirmed the higher expression of nuclear Myc localization in SerpinB3 
transgenic mice (Fig. 3). Conversely, in SerpinB3a(− /− ) mice the levels of Myc where significantly lower 
than those of control littermates, both in the cytoplasm and in the nucleus (Figs 1c and 3), overall sug-
gesting a predominant role of SerpinB3 in the regulation of Myc oncogene expression.
These results were in full agreement with findings obtained in human HCC specimens from a cohort 
of well characterized patients. Myc mRNA levels were detectable in 64% of the cases and showed a pos-
itive correlation with SerpinB3 transcript levels (Fig.  4a). The highest levels of Myc transcription were 
found in the sub-class of patients with high (> median value) SerpinB3 expression (Fig. 4b). Moreover, 
immunohistochemical analysis in serial paraffin sections revealed a prevalent nuclear localization of 
Myc in HCC areas showing high positivity for SerpinB3, while prevalent cytoplasmic localization was 
observed in HCC areas showing no/low positivity for SerpinB3, as shown in Fig. 4c. Despite these find-
ings, high Myc expression did not show significant clinical association with early tumor recurrence 
(p value = 0.3677), as previously described for SerpinB3 in the same cohort of patients32. In addition, by 
univariate and multivariate analysis, SerpinB3 and the severity of liver cirrhosis (identified with class B 
and C of CHILD-PUGH score34), but not Myc, were identified as independent variables associated to 
early HCC recurrence (Supplemental Table 1). These findings suggest a primary involvement of SerpinB3 
in hepatocarcinogenesis, while the presence of Myc might also enhance tumor aggressiveness and inva-
siveness potential.
SerpinB3 promotes mRNA expression of Myc target genes. In order to investigate whether the 
overexpression of Myc promoted by SerpinB3 was associated with an increased pro-oncogenic activ-
ity, we evaluated mRNA levels of four Myc target genes, including cyclin-dependent kinase 4 (CDK4), 
directly upregulated after Myc association with MAX, CDK activating phosphatase CDC25A35,36, 
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Prothymosin-alpha (PTMA) and Nucleophosmin (NPM1)37. As expected, CDK4, CDC25A, PTMA and 
also NPM1 were up-regulated in SerpinB3 transfected cells (Fig. 5a). These features were confirmed in 
human HCCs, where a significant up-regulation of Myc target genes was detected in HCCs with high 
SerpinB3 levels, as compared to human specimens with low SerpinB3 levels (Fig. 5b).
Modulatory effect of calpain. In order to investigate the possible mechanism responsible for nuclear 
translocation of Myc in cells expressing SerpinB3, we have explored whether this serpin may act through 
Figure 1. Expression, subcellular localization of Myc. (a) mRNA expression of Myc in HepG2 and 
Huh7 cells stably transfected with SerpinB3 (/SB3) or with the empty vector, as control (HepG2 or Huh7). 
Changes in mRNA gene expression were reported using the 2-Δ CT method. Values represent normalized 
mean expression ±  SEM of three independent experiments performed in triplicate. (b) Representative 
Myc western blot analysis and densitometric analysis results of three independent experiments performed 
on cytoplasmatic and nuclear extracts in control HepG2 cells and HepG2 cells transfected with SerpinB3 
(H/SB3). Values represent mean normalized expression ± SEM. (c) Representative western blot and 
densitometric analysis results of three independent experiments performed in SerpinB3-knockout mice 
(KO), in wild type C57BL/6 mice (WT) and in mice transgenic for human SerpinB3 (TG). The cropped gels 
shown in this figure have been run under the same experimental conditions and the values represent mean 
normalized expression  ± SEM of three independent experiments.
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its interaction with Calpain. This hypothesis relies on the recent finding indicating that Calpain (i.e., a 
cysteine protease) can cleave Myc in the cytoplasm14 and might represent a putative target for the cysteine 
protease inhibitor SerpinB3. Accordingly, a dose dependent reduction of Calpain activity was determined 
by employing recombinant SerpinB3, with a marked inhibition obtained at 20 nmol/L (Fig. 5c).
Modulatory effect of SerpinB3 on Myc-nick protein. In order to assess whether the amount of 
Myc-nick was modulated by SerpinB3, cytoplasmic Myc-nick was evaluated in HepG2 and HepG2/SB3 
cells using a specific antibody that recognizes the N-terminal portion of Myc (anti-Myc N262)14. The 
positivity of Myc-nick was observed only in cytoplasmic fractions and was more evident in HepG2 cells 
than in SerpinB3 transfected cells, while it was undetectable in nuclear fractions (Fig. 5d). In addition, 
the obtained results confirmed the increase of nuclear Myc protein levels in SerpinB3 transfected cells 
versus HepG2 control cells.
Our findings suggest that calpain inhibition by SerpinB3 may modulate the balance of cytoplasmic/
nuclear Myc by promoting its nuclear translocation as a result of an hampered production of Myc-nick.
Figure 2. Immunoflorescence results. Merge of contrast phase (first row) and indirect immunofluorescence 
(second and third row) analysis for SerpinB3 (red, Cy3) and Myc (green, 488) performed in control HepG2 
and in HepG2 cells overexpressing SerpinB3 (HepG2/SERPINB3). Nuclei are stained in blue (dapi). Original 
magnification are reported. Evaluation of immunoflorescence was assessed in three independent experiments 
examining at least ten random high-power fields.
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Modulatory effects of SerpinB3 on Yes-associated protein (Yap). In order to better understand 
the mechanism underlying the transcriptional overexpression of Myc promoted by SerpinB3, we have 
hypothesized a possible involvement of the Yes-associated protein (Yap), a master oncogene commonly 
found up-regulated in the majority of HCCs.
In order to evaluate Yap activity in vitro and in vivo, we performed Western Blot analysis in transfected 
HepG2 cells and in transgenic mouse livers, both overexpressing SerpinB3. Protein analysis revealed a 
remarkable nuclear translocation of Yap, especially in transfected HepG2 cells, as compared to controls 
(Fig. 6a,b). The Serpinb3a(− /− ) mouse livers did not show any significant change of Yap protein levels 
versus controls, as shown in Fig. 6b.
In order to confirm the increased pro-oncogenic transcriptional activity of Yap, induced by SerpinB3, 
the mRNA expression of the Yap target genes Survivin (or Birc5) and Axl receptor tyrosine kinase (AXL) 
was analyzed. HepG2 and Huh7 cells stably transfected to overexpress SerpinB3 revealed a significant 
Figure 3. Immunohistochemistry in mice liver. Representative image of immunohistochemistry for 
SerpinB3 and Myc in serial liver sections of SerpinB3-knockout mice (KO), wild type mouse and SerpinB3 
transgenic mice. Original magnifications are reported. Evaluation of immunostaining was assessed by two 
investigators examining at least ten random high-power fields.
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up-regulation of these two target genes, as compared to control cells (Fig. 6c,d). Of relevance, Yap mRNA 
levels were increased not only in transfected hepatoma cells (Fig. 6e), but also in human HCCs specimens 
with high SerpinB3 (Fig. 6f).
Modulatory effect of Yap siRNA on Myc expression in hepatoma cells. To assess the functional 
impact of decreased Yap expression in the transcriptional modulation of Myc gene exerted by SerpinB3 
in hepatoma cells, we knocked down Yap gene by lipofectamine transduction of siRNA. Real-time 
Figure 4. Myc and SerpinB3 in hepatocellular carcinoma. (a) Relationship between SerpinB3 and Myc 
mRNA in human HCCs. The axis represents the relative mRNA amount of the normalised genes, calculated 
by dividing the non-normalized values by the housekeeping genes and expressed as arbitrary units. The 
correlation analysis was performed with Spearman r test. (b) mRNA in human HCCs. Myc mRNA was 
analysed by qRT-PCR in relation to low expression (< median value; N = 52) or high expression (> median 
value; N = 15) of SerpinB3 mRNA. Central bars represent mean and external bars represent S.E.M. Statistical 
analysis was performed using Mann Whitney test. (c) Representative examples of immunohistochemistry for 
SerpinB3 and Myc counterstained with hematoxylin, in serial sections of a human HCC specimen with low 
expression of SerpinB3 and of a human HCC with high expression of SerpinB3. Original magnifications are 
reported.
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Figure 5. SerpinB3 modulatory effects on Myc target genes, calpain and cytoplasmic Myc-nick. 
(a) Quantitative mRNA analysis of the Myc target genes CDK4 and CDC25A in control HepG2 and Huh7 
cells and in the corresponding cells transfected with SerpinB3 (Hep/SB3 and Huh7/SB3). Values represent 
normalized mean ± SEM of three independent experiments performed in triplicate. (b) mRNA expression 
of the same Myc target genes in human HCC specimens, in relation to low (< median value) SerpinB3 
expression (N = 52) or high (> median value) SerpinB3 expression (N = 15). (c) The inhibitory effect of 
SerpinB3 on Calpain was examined using the commercially available Calpain activity assay Kit (Calbiochem, 
Merk Millipore, Darmstadt, Germany) that utilizes the Suc-LLVY-AMC as synthetic substrate. The release of 
the fluorescence product was monitored recording the fluorescence emission at 460 nm using an excitation 
wavelength of 360 nm with the Victor X3 multilabel plate reader (Perkin Elmer). The raw fluorescence data 
were expressed as relative fluorescence units (rfu). Inhibition experiments were performed using different 
amounts of SerpinB3 (range 0–20 nmol/L). (d) Modulatory effect of SerpinB3 on Myc-nick. Representative 
western blot protein analysis of Myc-nick on total extracts in control HepG2 and in HepG2 transfected 
with SerpinB3 (H/SB3) carried out with a specific antibody (anti-Myc N262) that recognizes the N-terminal 
portion of Myc.
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RT-PCR and immunoblot analysis confirmed down-modulation of Yap transcripts and protein at 72 h in 
both HepG2 and HepG2/SB3 cells (Fig. 7a,b).
Silencing of Yap determined also a remarkable reduction of Myc at mRNA and protein level (Fig. 7c,d) 
in HepG2/SB3 cells, suggesting that Yap may play an important role in promoting SerpinB3-induced 
transcription activity of Myc gene.
Figure 6. Modulatory effect of SerpinB3 on Yes-associated protein (Yap). (a) Example of Western blot 
analysis and corresponding densitometric analysis of Yap protein and its corresponding housekeeping bands 
performed on cytoplasmatic and nuclear extracts in control HepG2 and in HepG2 transfected with SerpinB3 
(H/SB3). The corresponding densitometric analysis obtained in three distinct experiments of Myc subcellular 
localization. (b) Example of Western blot analysis and corresponding densitometric analysis performed in 
SerpinB3a(− /− )mice (KO); Wild type C57BL/6 mice (WT) and mice transgenic for human SerpinB3 (TG). 
The corresponding densitometric analysis was obtained in three distinct experiments and the cropped gels 
have been run under the same experimental conditions. (c,d) Quantitative mRNA analysis of Yap target 
genes AXL and BIRC5 in control HepG2/Huh7 cells and the corresponding SerpinB3 transfected cells (Hep/
SB3 and Huh7/SB3). (e) mRNA expression of Yap in control HepG2/Huh7 cells and the corresponding 
SerpinB3 transfected cells (Hep/SB3 and Huh7/SB3). (f) mRNA expression of Yap in human HCC specimens 
in relation to low (< median value, N = 15) or high (> median value, N = 52) SerpinB3 expression. All values 
represent mean normalized expression ± SEM of three independent experiments performed in triplicate.
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Discussion
The precise modulation of Myc in the carcinogenesis process is still unclear. Among numerous potential 
oncogenic pathways, Myc has been observed to be a potent initiating oncogene for liver tumours and 
its inactivation is sufficient to induce sustained regression of Myc-initiated liver tumours in mice38. A 
frequent genetic abnormality seen in primary liver cancer is the overexpression of Myc. This oncogene 
assumes a pivotal role to determine HCC biology profile and a clinical value as predictor of poor out-
come in clinical setting. Myc was identified as one of four genes, including Sox2, Octamer-4 and KLF4, 
that could reprogram cells to a pluripotent stem cell state39. Along these lines, we have recently reported 
that SerpinB3 is highly expressed in hepatic stem/progenitor cell compartment of both foetal and adult 
livers40. In addition, this serpin was found highly expressed in hepatoblastomas, a tumor originating from 
liver embryonic cells and once again SerpinB3 levels were positively correlated with Myc expression33.
We recently reported that SerpinB3 expression was up-regulated by hypoxia through HIF-2α -dependent 
mechanisms in human liver cancer cells41. HIF-2α has a great oncogenic capacity and its overexpression 
correlates with poor patient outcome in colorectal carcinoma, melanoma, ovarian cancer and hepatocel-
lular carcinoma42–45, possibly also by promoting Myc activity through its binding to and stabilizing the 
Myc–Max heterodimer.
At variance with the Myc transgenic mouse model that is sufficient to induce liver cancer46, however, 
SerpinB3 transgenic mice do not develop any displasia or malignancies in the liver47. This discrepancy 
could be due to the fact that SerpinB3-overexpressing mice modulate only indirectly Myc gene, while the 
existence of other not yet discovered biological mechanisms determined by this serpin, that counteract 
Myc activity, at least from a phenotypic point of view, cannot be excluded.
Figure 7. Effect of Yap siRNA on Myc expression in SerpinB3 cells. Representative quantitative mRNA 
analysis (a) and western blot protein analysis (b) of Yap on total extracts in control HepG2 and in HepG2 
transfected with SerpinB3 (HepG2/SB3) silenced with siRNA Yap gene or transfected with non-silencing 
control (NsC). Representative quantitative mRNA analysis (c) and western blot protein analysis (d) of Myc 
on total extracts in control HepG2 and in HepG2 transfected with SerpinB3 (HepG2/SB3) silenced with 
siRNA Yap gene. Values represent mean gene expression  ± SEM.
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The present study has been designed to investigate and characterize the interplay and functional mod-
ulation of Myc by SerpinB3 in human liver cancer. Here we provide for the first time evidence indicating 
that Myc expression is significantly and mechanistically up-regulated by SerpinB3 through calpain and 
Hippo-dependent molecular mechanisms in human liver cancer cells and in a transgenic mice model. 
The finding of significantly lower levels of Myc in the liver of SerpinB3a(− /− ) mice further support 
the involvement of this serpin in the control of Myc expression. These findings were also confirmed in 
human samples of hepatocellular carcinoma, where the presence of high levels of SerpinB3 were corre-
lated with higher expression of Myc and of Yap pathway activation.
From a biological point of view, Myc overexpression by itself is not sufficient to be considered as 
an equivalent of its pro-oncogenic activity. Several inhibitors, such as Calpain or let-7 family, could in 
fact interfere at several levels with Myc, counteracting its onco-properties in the cell cytoplasm. Nuclear 
localization of Myc is required to promote target oncogene expression. In the present study we have 
demonstrated that the nuclear localization of Myc was strongly associated with the presence of SerpinB3, 
both in hepatocellular carcinoma and in different experimental models. Furthermore, the recombinant 
SerpinB3 protein was capable to inhibit the activity of Calpain in vitro, likely reducing its ability to cleave 
Myc in its cytoplasmic form.
The novelty of our findings is that SerpinB3 can improve the activity of Myc adopting different strate-
gies (Fig. 8). The first one is that intracellular SerpinB3 prevents Myc cytoplasmic retention, allowing its 
nuclear translocation, possibly blocking the cleavage exerted by Calpain that generates the non-oncogenic 
cytoplasmic Myc-nick form. Next, SerpinB3 is able to indirectly increase the transcription of Myc gene, 
probably through the induction of Yap pathway. Other mechanisms, however, cannot be excluded (e.g. 
the modulation of miRNA system) and deserve further studies. According to a recent report48, the action 
exerted by Yap on the miRNA-processing machinery is consistent with the miRNA profile induced by 
SerpinB3 in hepatoma cells49. The precise signal cascade leading to Myc overexpression still remains 
elusive and the biological influence of SerpinB3 on Yap and Hippo pathway should be further explored 
in detail by future studies.
In conclusion, the presented data provide further insights to our actual knowledge on the fine control 
of Myc modulation, possibly allowing the development of specifically designed and targeted drugs that 
may be able to more efficiently affect or prevent liver carcinogenesis.
Materials and Methods
Cell lines and culture conditions. HepG2 and Huh7 cells, derived from human hepatoma cells 
(LGC Standards S.r.l., Sesto San Giovanni, MI, Italy), were used. These cells were stably transfected with 
a plasmid vector carrying the wild-type SerpinB3 human gene (/SB3) or with the plasmid vector alone 
(pcDNA3.1D/V5-His-TOPO, Invitrogen Life Technologies, NY, USA), as previously reported28.
Mouse models. The study has been carried out on (12–14 weeks old) C57BL/6 mice transgenic for 
human SerpinB3 (N = 4), whose initial colony was kindly provided by Prof. Cassani (Tecnogen, Caserta, 
Italy)50. Wild type C57BL/6 mice (N = 6) of similar age were used as controls. Serpinb3a knockout mice 
(N = 3) (kindly provided by Dr. Gary Silverman and Dr. Cliff J. Luke, University of Pittsburg, Children’s 
Hospital, Pittsburg, PA) have been used as additional negative controls. All animals were kept under 
specific pathogen-free conditions and maintained with free access to pellet food and water at the Animal 
Care Facility of the Experimental Surgery Division of the University of Padua.
Figure 8. Hypothetical model of Myc modulation by SerpinB3. Proposed model depicting two strategies 
adopted by SerpinB3 to modulate Myc expression. 1. SerpinB3 determines an increase of Yap and its 
nuclear translocation, which can indirectly promote the increase of Myc transcription. 2. SerpinB3 blocks 
the Calpain-induced cleavage of Myc that determines its cytoplasmic retention, allowing the nuclear 
translocation of uncut Myc forms.
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Animals experiments, approved by the local Ethical committee and by the Italian Ministry of Health, 
were conducted in accordance with the Principles of laboratory animal care (NIH publication no. 85–23, 
revised 1985; http://grants1.nih.gov/grants/olaw/references/phspol.htm).
Patients and samples. In the present study we employed HCC specimens, obtained under written 
informed consent at the time of surgery in 67 patients with underlying cirrhosis of different etiology.
Clinical-pathological and molecular characteristics as well as follow-up procedures applied to these 
patients were described in a previous study32. All the patients underwent surgical resection as first-line 
therapy without pre-operative anticancer treatment and distant metastases. Tumour tissue samples were 
collected and part was formalin fixed and paraffin embedded, whereas the remaining part was immedi-
ately frozen at − 80 °C for transcript analysis. The use of human material conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki and all experimental protocols were approved by the Ethical 
Committee of our Institution.
Immunohistochemistry. Immunohistochemistry (IHC) was performed on formalin-fixed, 
paraffin-embedded specimens obtained from tumor liver samples as well as, from the liver of SerpinB3 
transgenic mice and related wild type mice. Briefly, paraffin sections (2μ m thick), mounted on 
poly-L-lysine coated slides, were incubated with primary antibody raised against SerpinB3 (1:1000, 
ThermoFisher Scientific, IL, USA on mouse liver tissue and 1:50, sc-21767 Santa Cruz Biotechnology, 
CA, USA on human liver tissue) and c-Myc (1:150, sc-788 Santa Cruz Biotechnology, CA, USA). After 
blocking endogenous peroxidase activity with 3% hydrogen peroxide and performing microwave antigen 
retrieval, primary antibodies were labeled by using EnVision, HRP-labeled System (DAKO) and visual-
ized by 3′ -diaminobenzidine substrate. For negative controls the primary antibodies were replaced by 
isotype- and concentrations-matched irrelevant antibody. Images of representative fields were captured 
by Leica Qwin Plus v3 software, under a CCD camera connected to a Leica microscope (Microsystem 
Imaging Solutions Ltd.).
Western Blot analysis. Total cell lysates or nuclear vs cytosolic extracts were subjected to sodium 
dodecyl sulfate-polyacrylamide gel-electrophoresis on acrylamide gels, incubated with desired pri-
mary antibodies, then with peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulins in 
Tris-buffered saline-Tween containing 2% (w/v) non-fat dry milk and finally developed with the ECL 
reagents, according to manufacturer’s instructions. Western Blot analysis was carried out in hepatoma 
cells transfected with SerpinB3 and in transgenic/knockout mice. The following specific antibodies were 
used: anti-SerpinB3 polyclonal antibody (1:500 Xeptagen SpA, Marghera, VE, Italy); anti-Myc mono-
clonal antibodies (1:1000, MYC clone 9E10, Santa Cruz Biotechnology, CA; anti-Myc polyclonal anti-
body (1:1000, clone N-262, SC-764, Santa Cruz Biotechnology, CA), anti-Myc polyclonal antibody (clone 
C-19, SC-788, Santa Cruz Biotechnology, CA), anti-YAP polyclonal antibody (1:200, YAP clone H-125, 
Santa Cruz Biotechnology, CA). Sample loading was evaluated by reblotting the same membrane with 
β -actin (1:1000, Sigma Aldrich) for total extract and α -tubulin (1:1000, Sigma Aldrich) or anti Lamin A 
(1:1000, SC-20680 Santa Cruz Biotechnology) for cytosolic or nuclear fraction respectively.
Immunofluorescence. Indirect immunofluorescence was performed on HepG2 and HepG2/SB3 
cells seeded on 6-well culture plates as described. Briefly, cells were fixed with methanol:acetone 1:1 
(v/v) for 20 min at − 20 °C, permeabilized with PBS containing 0.5% Triton X-100 and 0.05% NaN3 
for 10 min (room temperature) and incubated with primary antibodies SerpinB3 (1:100, ThermoFisher 
Scientific) and c-Myc (1:100, sc-788 Santa Cruz Biotechnology, CA) overnight at 4 °C. Immunopositivity 
was revealed by means of appropriate Cy3-conjugated antibodies (1:1000 dilution). Nuclei (blue fluores-
cence) were stained by treating cells with 4,6-diamidino-2-phenylindole (DAPI, 1 mg/ml in methanol) 
for 30 min at room temperature. Slides were then mounted with ELVANOL (Sigma-Aldrich, St. Louis, 
MO) and observed under fluorescence microscope (Leica).
mRNA quantification. Total RNA was extracted using RNasy Trizol (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. After determination of the purity and the integrity total 
RNA, complementary DNA synthesis, quantitative real-time PCR reactions (RT-PCR) were carried out 
as previously described32 using the CFX96 Real-Time instrument (Bio-Rad Laboratories Inc, Hercules, 
CA, USA).
In hepatoma cells and HCC samples the relative expression were generated for each sample by cal-
culating 2-Δ Ct51.
The following sets of primers were used: MYC-F: 5′ -aagacagcggcagcccgaac-3′ ; MYC-R: 5′ -tgggcg 
agctgctgtcgttg-3′ ; CDK4-F: 5′ -cagtgtacaaggcccgtgat-3′ ; CDK4-R: 5′ -cagtcgcctcagtaaagcca-3′ ; CDC25A-F: 
5-aggagtctccacctggaagac-3′ ; CDC25A R: 5′ -ccattcaaaacagagccataa-3′ ; AXL-F:5-gcaggctgaagaaagtccct-3′ ; 
AXL-R: 5′ -ctgtccatcccgaagccaat-3′ ; BIRC-F: 5′ -aggaccaccgcatctctacat-3′ ; BIRC-R: 5′ -aagtctggctcgttctcag 
tg-3′ ; YAP-F: 5′ -tcagacaacaacatggcagga-3′ ; YAP-R: 5′ -ttcatggctgaagccgagtt-3′ ; SerpinB3-F: 5′ -aactcct 
gggtggaaagtcaa-3′ ; SerpinB3-R: 5′ -accaatgtggtattgctgccaa-3′ ; NPM1-F: 5′ -ggttgtgaactaaaggccga-3′ ; 
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NPM1-R: 5′ -cctttgcaccagcccctaaa-3′ ; PTMA-F: 5′ -aaggagaagaaggaagttgtgga-3′ ; PTMA-R: 5′ -ctacctcatt 
gtcagcctcctg-3′ .
Calpain inhibition assay. The inhibitory effect of SerpinB3 on calpain was examined using the com-
mercially available Calpain activity assay Kit (Calbiochem, Merk Millipore, Darmstadt, Germany) that 
utilizes the Suc-LLVY-AMC as synthetic substrate. Inhibition experiments were performed using dif-
ferent amounts of human recombinant SerpinB3 protein52 (range 0–20 nmol/L). 60μ l of human calpain 
1 (100 nmol/L) was mixed with increasing amounts of inhibitor (SerpinB3) in presence of 60μ l of sub-
strate at 1:100 dilution. Calpain activation buffer containing Ca2+ and the reducing agent TCEP (Tris 
2-carboxyethyl phosphine hydrochloride) were added to the reaction mixture, to obtain a final volume of 
230μ l. The reaction was started by rapidly mixing of calpain in the reaction mixture and the formation 
of the fluorescent product was monitored over time. The release of the fluorescence product (AMC) was 
monitored recording the fluorescence emission at 460 nm using the Victor X3 multilabel plate reader 
(Perkin Elmer) at the excitation wavelength of 360 nm. The raw fluorescence data were expressed as 
Relative Fluorescence Units (RFU).
YAP silencing by small RNA interference. RNA interference experiments to knockdown Yap 
expression in HepG2 cells were performed using siRNA duplex (Qiagen Italia, Milano, Italy) as previously 
described53. The following target sequences were used: YAP F: 5′ -GGUGAUACUAUCAACCAAATT-3;
YAP R: 5′ -UUUGGUUGAUAGUAUCACCTG-3′ . The siRNAs and related non-silencing controls 
were transfected in HepG2 cells and in HepG2/SerpinB3 with Lipofectamine 2000 transfection reagent 
(Life Technologies Italia, Monza, Italy) according to manufacturer’s instructions up to 72 hrs.
Statistical analysis. Data in bar graphs represent means ± SEM and were obtained from average 
data of at least three independent experiments performed in triplicate. Luminograms and morphological 
images are representative of at least three experiments with similar results. Statistical analysis for these 
experiments was performed by Student’s t-test (and Nonparametric test) or ANOVA for analysis of var-
iance when appropriate. All tests were two-sided. Clinical significance of Myc in tumours samples was 
assessed by analyzing its expression in relation to time to recurrence, where early recurrence was defined 
as HCC reappearance within 12 months from radical resection. Kaplan–Meier curves were performed 
according to Myc expression in patients with high (> median value) expression of Myc compared with 
patients with low levels of Myc and statistical analysis was performed using log-rank (Mantel–Cox) test. 
Univariate and multivariate logistic regression analysis were carried out to identify clinical and/or molec-
ular predictors of early tumor recurrence. For multivariate analysis only variables achieving a significant 
result in univariate analysis were included. For molecular variables a cut-off value > median value was 
defined as “high-mRNA expression” to be considered as a dichotomous categorical variable, compared 
to the remaining cases, defined as “low- mRNA expression” as previously described32. The calculations 
were carried out with Graph Pad InStat Software (San Diego,CA) and SPSS 21.0 software (SPSS Inc, 
Chicago,IL). The null hypothesis was rejected at p < 0.05.
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